Details
Stereochemistry | ACHIRAL |
Molecular Formula | 7Mo.24O.4H2O.6H4N |
Molecular Weight | 1235.86 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | -42 |
SHOW SMILES / InChI
SMILES
[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].[NH4+].O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo]
InChI
InChIKey=JYJVMQULBZTBKM-UHFFFAOYSA-T
InChI=1S/7Mo.6H3N.4H2O.24O/h;;;;;;;6*1H3;4*1H2;;;;;;;;;;;;;;;;;;;;;;;;/q;;;;;;;;;;;;;;;;;24*-2/p+6
Molecular Formula | H3N |
Molecular Weight | 17.0305 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Mo |
Molecular Weight | 95.94 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19711110&CC=GB&NR=1252799A&KC=Ahttps://www.drugs.com/cons/ammonium-molybdate-intravenous-injection.html | https://www.ncbi.nlm.nih.gov/pubmed/27055119 | https://www.ncbi.nlm.nih.gov/pubmed/26435257 | https://www.ncbi.nlm.nih.gov/pubmed/10382558 | https://www.ncbi.nlm.nih.gov/pubmed/24470099 | https://www.cancercarewny.com/content.aspx?chunkiid=111707
Sources: https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19711110&CC=GB&NR=1252799A&KC=Ahttps://www.drugs.com/cons/ammonium-molybdate-intravenous-injection.html | https://www.ncbi.nlm.nih.gov/pubmed/27055119 | https://www.ncbi.nlm.nih.gov/pubmed/26435257 | https://www.ncbi.nlm.nih.gov/pubmed/10382558 | https://www.ncbi.nlm.nih.gov/pubmed/24470099 | https://www.cancercarewny.com/content.aspx?chunkiid=111707
Molybdenum (Mo) is an essential trace element and is a component of vitamin and mineral supplements. Molybdenum has essential biological roles in organisms and microorganisms. Molybdenum is the only trace metal of the second
row of the periodic table that exhibits biological activity
when it is ligated to a cofactor. It acts as a critical cofactor in several molybdenum-dependent enzymes that are involved in important cellular reactions and pathways, including xanthine oxidoreductase. In nature two principal
concepts of Mo cofactors have evolved, one is the iron Mo
cofactor in bacterial nitrogenase and the other is represented by a large family of enzymes with more than
100 representatives relying on the pterin-based Mo cofactor (Moco). Moco-containing enzymes catalyze key
redox reactions in the global carbon, sulfur and nitrogen
cycles. Four molybdenum-dependent enzymes are known in humans, each harboring a pterin-based molybdenum cofactor (Moco) in the active site. In these enzymes, molybdenum catalyzes oxygen transfer reactions from or to substrates using water as oxygen donor or acceptor. Molybdenum shuttles between two oxidation states, Mo(IV) and Mo(VI). Following substrate reduction or oxidation, electrons are subsequently shuttled by either inter- or intra-molecular electron transfer chains involving prosthetic groups such as heme or iron-sulfur clusters. In all organisms studied so far, Moco is synthesized by a highly conserved multi-step biosynthetic pathway. A deficiency in the biosynthesis of Moco results in a pleitropic loss of all four human Mo-enzyme activities and in most cases in early childhood death. For the general population, the diet is the most important source of molybdenum and concentrations in water and air usually are negligible. The average daily dietary intake is about 0.1-0.5 mg m.o. Molybdenum is marketed both as a tablet and as a liquid supplement containing the mineral in dissolved form. Despite widespread claims, there is no evidence that one form of molybdenum is absorbed to a markedly superior extent than any other. Current marketing of molybdenum products for the treatment of medical conditions is not founded on any meaningful scientific evidence. People with serious kidney disease should avoid taking molybdenum (or any other supplement) except on the advice of a physician. People with serious kidney disease should also avoid taking molybdenum (or any other supplement) except on the advice of a physician.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Molecular basis of proton motive force generation: structure of formate dehydrogenase-N. | 2002 Mar 8 |
|
Functional characteristics of NaS2, a placenta-specific Na+-coupled transporter for sulfate and oxyanions of the micronutrients selenium and chromium. | 2006 Jun-Jul |
|
Possible effects of metallosis on spermatozoal apoptotic genes expression in individuals with intramedullary nailing prosthesis. | 2014 Jun |
|
Study of antitumor effect of selected vanadium and molybdenum organometallic complexes in human leukemic T-cells. | 2015 Dec 5 |
|
The Co-induced Effects of Molybdenum and Cadmium on Antioxidants and Heat Shock Proteins in Duck Kidneys. | 2015 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/molybdenum.html
Dietary Considerations
Dietary reference intake (IOM, 2011):
0 to 6 months: Adequate intake: 2 mcg daily
7 to 12 months: Adequate intake: 3 mcg daily
1 to 3 years: RDA: 17 mcg daily
4 to 8 years: RDA: 22 mcg daily
9 to 13 years: RDA: 34 mcg daily
≥14 to 18 years: RDA: 43 mcg daily
>18 years: RDA: 45 mcg daily
Pregnancy and lactation: RDA: 50 mcg daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:02:03 GMT 2023
by
admin
on
Fri Dec 15 17:02:03 GMT 2023
|
Record UNII |
OGI154X474
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11128
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | |||
|
SUB22764
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | |||
|
SUB12880MIG
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | |||
|
OGI154X474
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | |||
|
86244
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | |||
|
m1800
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
485454
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | |||
|
C022175
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | |||
|
17789
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | RxNorm | ||
|
12054-85-2
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY | |||
|
100000088567
Created by
admin on Fri Dec 15 17:02:04 GMT 2023 , Edited by admin on Fri Dec 15 17:02:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE |